NRG GU007

Primary Category:

Radiation Oncology

Disease Category:

Genitourinary, Prostate

Status:

Open

Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)

 

NCT#04037254

GU007 is reopened to accrual to enroll 1 additional patient to dose level 2 of the phase I trial portion, effective 09/14/21.  Upon accrual of 1 additional patient, protocol will temporarily close for approximately 2 months for a protocol-specified toxicity analysis.